Vanda Pharmaceuticals Reports Q2 2025 Financial Results

Vanda Pharmaceuticals ( (VNDA) ) has released its Q2 earnings. Here is a breakdown of the information Vanda Pharmaceuticals presented to its investors.

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to address unmet medical needs, particularly in the areas of neurology and psychiatry.

In its second quarter of 2025 financial report, Vanda Pharmaceuticals highlighted a significant increase in net product sales for its key drug, Fanapt, while also noting the acceptance of new drug applications for Bysanti and Tradipitant by the FDA, which could potentially expand its product portfolio.

The company reported total net product sales of $52.6 million for the quarter, marking a 4% increase from the previous year. Fanapt sales rose by 27%, driven by enhanced sales efforts and a direct-to-consumer campaign. However, sales for other products like HETLIOZ and PONVORY saw declines. Despite the revenue growth, Vanda experienced a net loss of $27.2 million, significantly higher than the previous year’s loss.

Vanda is actively pursuing regulatory approvals for new treatments, with Bysanti and Tradipitant under FDA review and potential market entries in 2026. The company is also preparing to submit a Biologics License Application for Imsidolimab, aiming to further strengthen its clinical pipeline.

Looking ahead, Vanda Pharmaceuticals remains focused on achieving its financial objectives for 2025, with anticipated revenues between $210 to $250 million and maintaining a strong cash position. The company is optimistic about its growth trajectory, driven by ongoing product development and strategic market initiatives.